{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:00:58Z","timestamp":1785301258848,"version":"3.55.0"},"reference-count":72,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,1,31]]},"DOI":"10.2217\/fon-2017-0298","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T15:35:13Z","timestamp":1508772913000},"page":"137-150","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["An Updated Review of the\n            <i>JAK1\/2<\/i>\n            Inhibitor (Ruxolitinib) in the Philadelphia-Negative Myeloproliferative Neoplasms"],"prefix":"10.1080","volume":"14","author":[{"given":"Natalia","family":"Curto-Garcia","sequence":"first","affiliation":[{"name":"Department of Haematology, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695940"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09179.x"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/284706"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.04.011"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.02.031"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-293415"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-575373"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08448"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.208"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.57"},{"issue":"21","key":"e_1_3_3_17_1","first-page":"431","article-title":"Prognostic impact of mutations in a large series of patients with myelofibrosis","volume":"120","author":"Guglielmelli P","year":"2012","unstructured":"Guglielmelli P , BiamonteF, PereiraAet al. Prognostic impact of mutations in a large series of patients with myelofibrosis. ASH Annual Meeting Abstracts120(21), 431 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29842"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3145"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1353-5"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0279"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70102-5"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.272"},{"key":"e_1_3_3_25_1","unstructured":"FDA Label Information for Jakafi\u2122 (Ruxolitinib) tablets FOUIUSA\n. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202192lbl.pdf."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.323"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1185414"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0284-z"},{"issue":"21","key":"e_1_3_3_34_1","first-page":"177","article-title":"Expand: a Phase Ib, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 \u00d7 109\/l and 99 \u00d7 109\/l","volume":"120","author":"Harrison CN","year":"2012","unstructured":"Harrison CN , GisslingerH, MillerCBet al. Expand: a Phase Ib, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 \u00d7 109\/l and 99 \u00d7 109\/l. ASH Annual Meeting Abstracts120(21), 177 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-81"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13379"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3365.3365"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695965"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143644"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"e_1_3_3_42_1","first-page":"182071","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80 week follow-up from the RESPONSE-2 trial","volume":"2017","author":"Greisshammer M","year":"2017","unstructured":"Greisshammer M , SaydamG, PalandriFet al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80 week follow-up from the RESPONSE-2 trial. EHA Annual Meeting Abstracts Haematologica2017, 182071 (2017).","journal-title":"EHA Annual Meeting Abstracts Haematologica"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14382"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0169"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12985"},{"issue":"21","key":"e_1_3_3_46_1","first-page":"313","article-title":"Durable responses with the JAK1\/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU)","volume":"116","author":"Verstovsek S","year":"2010","unstructured":"Verstovsek S , PassamontiF, RambaldiAet al. Durable responses with the JAK1\/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). ASH Annual Meeting Abstracts116(21), 313 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-624536"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28441"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1847.1847"},{"issue":"101","key":"e_1_3_3_50_1","first-page":"93","article-title":"Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in MAJIC \u2013 an investigator lead randomised trial","volume":"101","author":"Harrison CN","year":"2016","unstructured":"Harrison CN , MeadA, PanchalAet al. Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in MAJIC \u2013 an investigator lead randomised trial. EHA Annual Meeting Abstracts Haematologica101(101S), 93 (2016).","journal-title":"EHA Annual Meeting Abstracts Haematologica"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.LBA-5.LBA-5"},{"key":"e_1_3_3_53_1","article-title":"Phase III randomized trial of momelotinib versus ruxolitinib in JAK inhibitor naive patients with myelofibrosis: results of the SIMPLIFY-1study","author":"Gotlib JR","year":"2017","unstructured":"Gotlib JR , KiladjianJJ, CatalanoJVet al. Phase III randomized trial of momelotinib versus ruxolitinib in JAK inhibitor naive patients with myelofibrosis: results of the SIMPLIFY-1study. EHA Annual Meeting Abstracts Haematologica182072 (2017).","journal-title":"EHA Annual Meeting Abstracts Haematologica"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151126"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.4060.4060"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.825.825"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.984703"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.827.827"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-742288"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.56.56"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.478.478"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15593"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.256"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0298-6"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0542-7"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23871"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1337507"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.916273"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.235"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1936-5"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0518"},{"issue":"7","key":"e_1_3_3_74_1","first-page":"832","article-title":"Does ruxolitinib prolong the survival of patients with myelofibrosis?","volume":"129","author":"Francisco Cervantes and Arturo Pereira","year":"2016","unstructured":"Francisco Cervantes and Arturo Pereira . Does ruxolitinib prolong the survival of patients with myelofibrosis?Blood129(7), 832\u2013837 (2016).","journal-title":"Blood"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:59Z","timestamp":1719125099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1,31]]}},"alternative-id":["10.2217\/fon-2017-0298"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0298","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}